Trials / Completed
CompletedNCT00533611
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0524A, /Duration of Treatment : 4 Weeks | |
| DRUG | Comparator : niacin /Duration of Treatment : 1 Weeks |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2007-09-21
- Last updated
- 2017-02-17
Source: ClinicalTrials.gov record NCT00533611. Inclusion in this directory is not an endorsement.